These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 9490273)

  • 1. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
    Karamitopoulou E; Perentes E; Tolnay M; Probst A
    Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
    Abramovich CM; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
    Abramovich CM; Prayson RA
    Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
    Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
    J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different responses of benign and atypical meningiomas to gamma-knife radiosurgery: report of two cases with immunohistochemical analysis.
    Kawashima M; Suzuki SO; Ikezaki K; Matsushima T; Fukui M; Iwaki T
    Brain Tumor Pathol; 2001; 18(2):61-6. PubMed ID: 11908875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
    Abramovich CM; Prayson RA
    Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas.
    Konstantinidou A; Korkolopoulou P; Patsouris E; Mahera H; Hranioti S; Kotsiakis X; Davaris P
    J Neurooncol; 2001 Oct; 55(1):1-9. PubMed ID: 11804277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
    Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
    Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis is associated with atypical or malignant change in meningiomas. An in situ labelling and immunohistochemical study.
    Ng HK; Chen L
    Histopathology; 1998 Jul; 33(1):64-70. PubMed ID: 9726051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations].
    Taddei GL; Caldarella A; Raspollini MR; Taddei A; Buccoliero AM
    Pathologica; 2002 Feb; 94(1):10-5. PubMed ID: 11912872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 overexpression and proliferative potential in malignant meningiomas.
    Nagashima G; Aoyagi M; Yamamoto M; Yamamoto S; Wakimoto H; Ohno K; Yamamoto K; Hirakawa K
    Acta Neurochir (Wien); 1999; 141(1):53-61; discussion 60-1. PubMed ID: 10071687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation and DNA fragmentation in meningioma subtypes.
    Maier H; Wanschitz J; Sedivy R; Rössler K; Ofner D; Budka H
    Neuropathol Appl Neurobiol; 1997 Dec; 23(6):496-506. PubMed ID: 9460716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
    Ho DM; Hsu CY; Ting LT; Chiang H
    Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity.
    Arena S; Barbieri F; Thellung S; Pirani P; Corsaro A; Villa V; Dadati P; Dorcaratto A; Lapertosa G; Ravetti JL; Spaziante R; Schettini G; Florio T
    J Neurooncol; 2004 Jan; 66(1-2):155-66. PubMed ID: 15015781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
    Devaprasath A; Chacko G
    Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.